Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Arcturus Therapeutics (ARCT – Research Report). The associated price target is $45.00.
Yanan Zhu has given a Buy rating to Arcturus Therapeutics based on a combination of promising developments and expected milestones in the year 2024. Zhu points to the anticipated launch of the company’s COVID-19 vaccine in Japan, as well as a potential approval in the European Union, as key drivers of potential growth. Additionally, the company’s ability to demonstrate multivalent vaccine capabilities through upcoming data readouts is seen as a significant strength of its self-amplifying RNA (saRNA) technology platform.
Further bolstering this optimistic outlook, Zhu highlights Arcturus’s competitive manufacturing processes, which require less RNA per dose compared to peers, potentially leading to cost advantages. The maturation of the company’s multivalency technology is underscored by expected data from studies on a bivalent COVID-19 vaccine and a quadrivalent flu vaccine. These advancements, combined with anticipated interim data from Phase 2 studies in Ornithine Transcarbamylase Deficiency (OTCD) and Phase 1 studies in Cystic Fibrosis (CF), contribute to the positive assessment and recommendation to Buy ARCT shares.
In another report released on January 10, Piper Sandler also assigned a Buy rating to the stock with a $140.00 price target.
ARCT’s price has also changed slightly for the past six months – from $30.990 to $33.150, which is a 6.97% increase.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Arcturus Therapeutics (ARCT) Company Description:
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Read More on ARCT:
- PassPort Technologies starts collaborative research with Arcturus Therapeutics
- The biotech stocks to own in 2024, according to Piper Sandler
- Arcturus Therapeutics and CSL’ ARCT-154 shows superior immunogenicity
- Arcturus Therapeutics, CSL publish data on booster dose of ARCT-154
- Arcturus Therapeutics initiated with bullish view at Canaccord, here’s why
